ERBB2 and gastric cancer: HER2 overexpression is used as a biomarker in breast and gastric cancers to predict the response to anti-HER2 monoclonal antibody therapies (trastuzumab and pertuzumab) and small-molecule HER2 kinase inhibitors (lapatinib) [5, 6].